Month: September 2023
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that preclinical data supporting STAR-0215’s profile as a potential long-acting therapy for hereditary angioedema (HAE) dosed once every three…
Read More
You should not have to compromise your study design simply because your eClinical Technology does not support your unique study requirements. At TrialStat we do things differently. We believe that you should not have to compromise and to make that a reality, we specialize in Custom Validated Development. Whether it’s a small change in workflow,…
Read More
– CABINET trial will be unblinded and stopped early due to a dramatic improvement in efficacy per a unanimous recommendation by The Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board – – Based on positive results, findings will be discussed with the U.S. Food and Drug Administration – Excerpt from the…
Read More- « Previous
- 1
- 2
- 3